PTC Therapeutics (PTCT) PT Raised to $43 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
PTC Therapeutics (PTCT) PT Raised to $51 at RBC Capital
August 8, 2018 8:50 AM EDTRBC Capital raised its price target on PTC Therapeutics (NASDAQ: PTCT) to $51.00 (from $48.00) while maintaining a Outperform rating.
Abrahams expects the stock to gain as it continues to leverage their DMD cash flows and commercial/R&D infrastructure to diversify into new... More
